{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:35:10Z","timestamp":1761057310686},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,9,22]],"date-time":"2008-09-22T00:00:00Z","timestamp":1222041600000},"content-version":"vor","delay-in-days":2397,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> The aim of our study was to compare the activity of cetirizine 10\u2003mg with that of mizolastine 10\u2003mg <jats:italic>vs<\/jats:italic> placebo at 24\u2003h after intake in healthy volunteers.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> This was a double\u2010blind, randomized, placebo controlled, three\u2010way cross\u2010over study with a wash\u2010out period of 7\u00b12 days between each period. The study included 36\u2003healthy volunteers (18\u201350 years, mean age\u2003=\u200332 years; 9 males). The objective measurement was the cutaneous reactivity to increasing concentrations of histamine (0, 5, 10, 20, 40, 80, 160\u2003mg\u2003ml<jats:sup>\u22121<\/jats:sup>) administered by prick tests. The reactivity was evaluated by the wheal and flare areas (mm<jats:sup>2<\/jats:sup>). The AUC (area under curves) values of the wheal and flare areas as a function of the log<jats:sub>2<\/jats:sub> transformed histamine concentration were calculated for each subject and treatment, and compared.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A highly significant treatment effect was evidenced both for wheal and flare responses (<jats:italic>P<\/jats:italic>\u2003=\u20030.0001). This indicates the good activity of both cetirizine 10\u2003mg and mizolastine 10\u2003mg in inhibiting skin wheal and flare reactions to histamine. In addition, the mean AUC values significantly differed between cetirizine and mizolastine (64.8 and 117.8 log<jats:sub>2<\/jats:sub> (mg\u2003ml<jats:sup>\u22121<\/jats:sup>)\u2003\u00d7\u2003mm<jats:sup>2<\/jats:sup> for wheal, and 939.4 and 2340.8 for flare, respectively; <jats:italic>P<\/jats:italic>\u2003=\u20030.0001), with a superior activity of cetirizine than mizolastine at 24\u2003h after intake both on wheal and flare responses. The tolerance of cetirizine and mizolastine was good. The severity of the adverse events was never more than \u2018moderate\u2019, \u2018fatigue\u2019 being the most frequent reported symptom [cetirizine (6 subjects), placebo (3), mizolastine (5)], followed by \u2018somnolence\u2019[cetirizine (0), placebo (1), mizolastine (3)]. There was no serious adverse event.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> This study shows that cetirizine (10\u2003mg) suppresses skin reactivity to histamine more effectively than mizolastine (10\u2003mg) 24\u2003h after intake in healthy volunteers.<\/jats:p>","DOI":"10.1046\/j.0306-5251.2001.01551.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:44:46Z","timestamp":1047357886000},"page":"250-254","source":"Crossref","is-referenced-by-count":14,"title":["Comparative activity of cetirizine and mizolastine on histamine\u2010induced skin wheal and flare responses at 24\u2003h"],"prefix":"10.1111","volume":"53","author":[{"given":"A.","family":"Purohit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"M\u00e9lac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Frossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346060-00008"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040050-00009"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04065.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF02802294","article-title":"Cetirizine. An updated review of its pharmacological properties and therapeutic efficacy","volume":"11","author":"Rihoux JP","year":"1993","journal-title":"Clin Rev Allergy"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb00976.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199809000-00006"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb07103.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(90)90091-H"},{"key":"e_1_2_6_10_2","first-page":"498","article-title":"Comparison of cetirizine and terfenadine in the treatment of chronic idiopathic urticaria","volume":"65","author":"Kietzmann H","year":"1990","journal-title":"Ann Allergy"},{"key":"e_1_2_6_11_2","first-page":"27","article-title":"Dose ranging study. Cetirizine in the treatment of atopic dermatitis in adults","volume":"70","author":"Hannuksela M","year":"1993","journal-title":"Ann Allergy"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247671"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62941-9"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050677"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62483-0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161020-00006"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00007.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(92)90156-V"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006059101900213"},{"key":"e_1_2_6_20_2","first-page":"251","article-title":"Lack of subsensitivity to mizolastine over 8\u2010week treatment","volume":"51","author":"Bousquet J","year":"1996","journal-title":"Allergy"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00927.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920050-00001"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1999.0290s3156.x"},{"key":"e_1_2_6_24_2","first-page":"179","article-title":"Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis","volume":"48","author":"Goldhill J","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_25_2","first-page":"173","article-title":"Anti\u2010inflammatory properties of mizolastine after oral administration on arachidonic acid\u2010induced cutaneous reaction in the rat","volume":"48","author":"Pichat P","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63417-5"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006059802600603"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb01026.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2222.1999.00005.x","article-title":"Rapid symptom relief in rhinitis","volume":"29","author":"Bousquet J","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62672-5"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006059902700603"},{"key":"e_1_2_6_32_2","first-page":"205","article-title":"Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group","volume":"10","author":"Leynadier F","year":"2000","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00014.x"},{"key":"e_1_2_6_34_2","first-page":"135","article-title":"Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine","volume":"69","author":"Rosenzweig P","year":"1992","journal-title":"Ann Allergy"},{"key":"e_1_2_6_35_2","first-page":"459","article-title":"Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers","volume":"40","author":"Rosenzweig P","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04154.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936050-00003"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62436-2"},{"key":"e_1_2_6_39_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2222.1999.00002.x","article-title":"Mizolastine: antihistaminic activity from preclinical data to clinical evaluation","volume":"29","author":"Simons FE","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2000.tb00423.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(91)90183-O"},{"key":"e_1_2_6_42_2","first-page":"31","article-title":"The metabolism and pharmacokinetics of 14C\u2010cetirizine in humans","volume":"59","author":"Wood SG","year":"1987","journal-title":"Ann Allergy"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0306-5251.2001.01551.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0306-5251.2001.01551.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.0306-5251.2001.01551.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:48:53Z","timestamp":1697539733000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.0306-5251.2001.01551.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1046\/j.0306-5251.2001.01551.x"],"URL":"https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01551.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}